ROS1 Proto Oncogene
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC (NCT01945021) | Pfizer | 2013-09-30 |
Track ROS1 Proto Oncogene automatically
Every clearance here is in the API, with alerts when new ones post.